Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone Regimens in Duchenne Muscular Dystrophy
NCT07787689Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in Duchenne muscular dystrophy (DMD) (2 arms). Primary endpoint: Treatment efficacy at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07787689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787689.